Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07310446 · ClinicalTrials.gov registry record
Collection of Samples From the United States Population for Optimization and Evaluation of Colorectal Cancer (CRC) Plasma Circulating Free-DNA (cfDNA) Marker Panel Performance
A clinical trial of Colorectal Cancer, sponsored by Universal Diagnostics.
- Recruiting
- Registry status
- 6,500
- Enrollment target
- 1
- Study location
NCT07310446 is a study of Colorectal Cancer that is actively recruiting participants, run by Universal Diagnostics. The registered enrollment target is 6,500 participants, above the 1,494-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (335% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07310446, a study of Colorectal Cancer, is actively recruiting participants, sponsored by Universal Diagnostics.
- RECRUITING
- Registry status
- 6,500 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to prospectively collect blood samples and clinical data from patients that have been newly diagnosed with colorectal cancer and scheduled for resection surgery but are pre cancer treatment, subjects who are NOT scheduled for surgery but have histological confirmation of CRC from the diagnostic colonoscopy and clinical staging (cTMN) is available and are pr e- treatment, and patients who are at average risk of colorectal cancer and who are scheduled for routine colonoscopy examinations.
Conditions Studied
Study Locations (1)
Illinois
- Gastroenterology and Internal Medicine Specialists - Lake Barrington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,500 participants |
| Start Date | 2023-07-31 |
| Est. Completion | 2027-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07310446
The ClinicalTrials.gov registry entry for NCT07310446 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 6,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,494-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (335% higher). The listed sponsor is Universal Diagnostics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT07310446 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT07310446 about?
NCT07310446 is a clinical study titled "Collection of Samples From the United States Population for Optimization and Evaluation of Colorectal Cancer (CRC) Plasma Circulating Free-DNA (cfDNA) Marker Panel Performance". This study is designed to prospectively collect blood samples and clinical data from patients that have been newly diagnosed with colorectal cancer and scheduled for resection surgery but are pre cancer treatment, subjects who are NOT scheduled for surgery but have histological confirmation of CRC f...
What is the current status of trial NCT07310446?
This trial is currently recruiting. The enrollment target is 6,500 participants. The study started on 2023-07-31. Estimated completion is 2027-07.
What conditions does trial NCT07310446 study?
This clinical trial studies the following conditions: Colorectal Cancer.
Who is sponsoring clinical trial NCT07310446?
This trial is sponsored by Universal Diagnostics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07310446 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
Resistance Exercise and Creatine in Colorectal Cancer
RECRUITING · NA
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.